Clinical ink

Clinical ink

制药业

Winston-Salem,NC 8,192 位关注者

关于我们

Clinical ink is the global life science company that brings data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.

网站
https://www.clinicalink.com
所属行业
制药业
规模
201-500 人
总部
Winston-Salem,NC
类型
私人持股
领域
Clinical Trials、eSource、Electronic Data Capture、Risk Based Monitoring、Adaptive Design、Regulatory Submissions、ePRO、eCOA、Decentralized Trials、Cognitive Assessment、Oncology、Immunology、CNS、Alzheimers、Life Sciences、Parkinson's、Direct Data Capture、DDC、Digital Biomarkers和Digital Endpoints

地点

  • 主要

    525 Vine Street

    Suite 130

    US,NC,Winston-Salem,27101

    获取路线

Clinical ink员工

动态

  • Clinical ink转发了

    查看David Anderson的档案,图片

    Director, Science & Innovation | Neuroscientist | Data Scientist

    We are pleased to report another publication from the WATCH-PD study, in which Clinical ink's Movement Disorder platform was used to remotely monitor Parkinsonian symptoms using a multi-domain collection of sensor and wearable capabilities. In this work, we developed a high-dimensional feature engineering library to construct classification models of PD status. Highlights from this study include: High classification accuracy --> our model predicted PD status with 92% accuracy, 90% sensitivity, and 100% specificity, providing a level of accuracy higher than standard clinical methods in early PD Environment agnostic --> our model was able to predict PD status in both clinic and home environments, allowing for remote home administration with the same level of performance as when completed in clinic Platform agnostic --> our features and models were able to perform well when applied to data from the mPower study, demonstrating applicability across studies and platforms Enormous thanks for our collaborators on this work: Ray Dorsey, Jamie Adams, Melissa Kostrzebski, MS, MBA, Josh Cosman, Tairmae Kangarloo, Joan Severson, Steve Polyak, Ph.D., Shane Johnson, PhD, Michalis Kantartjis, Allen Best, Daniel Jackson Amato, Brian Severson, Anna Revelez, Michael Merickel, Sean Jezewski

    Wearable Sensor-Based Assessments for Remotely Screening Early-Stage Parkinson’s Disease

    Wearable Sensor-Based Assessments for Remotely Screening Early-Stage Parkinson’s Disease

    mdpi.com

  • 查看Clinical ink的公司主页,图片

    8,192 位关注者

    Clinical ink is pleased to announce the launch of EDCXtra?, an innovative Electronic Data Capture (EDC) system.?EDCXtra is based on the company’s best in class direct data capture (DDC)/eSource platform, which has evolved over 17 years, and resulted in multiple FDA approvals.?EDCXtra incorporates all existing DDC functionality into a single web-based application which includes Clinical ink’s industry leading electronic Clinical Outcome Assessments (eCOAs) and eConsent solutions, providing a comprehensive, all-in-one GCP compliant platform. ? Read more about EDCXtra in our press release here: https://lnkd.in/ehEKmxi6

    Clinical ink announces EDCXtra

    Clinical ink announces EDCXtra

    https://www.clinicalink.com

  • 查看Clinical ink的公司主页,图片

    8,192 位关注者

    Are you attending?the MASH Drug Development Summit?in Boston, September 24-26? Join Clinical ink’s?David Anderson?on Wednesday, September 25 as he presents a comprehensive digital platform used for remotely monitoring MASH/MASLD symptoms, determining risk of non-adherence, and providing personalized interventions to enhance adherence and retention in clinical trials. For more information on how to get MASH/MASLD data, insights, and decisions to your clinical teams faster, please contact?Craig Hatton. https://lnkd.in/eQF_RzUA

    8th MASH Summit 2024 | September 24-26 Boston, MA

    8th MASH Summit 2024 | September 24-26 Boston, MA

    mashdrugdevelopmentsummit.com

  • 查看Clinical ink的公司主页,图片

    8,192 位关注者

    We are delighted to welcome our new Chief Medical Officer, Dr. Nicholas Alp, MD PhD FACC.?Dr. Alp brings more than 30 years of clinical research expertise to Clinical ink, and will lead the creation of innovative solutions and commercial strategies for clinical trial technology based on his experience as an interventional cardiologist and clinical trialist. Read the announcement here: https://lnkd.in/eBFijFst

    • 该图片无替代文字
  • Clinical ink转发了

    查看Tim BEARPARK, MSc, MBA, DCR(T)的档案,图片

    ? VP ?? Transformational Leader ?? Business Growth Strategy and Scaling ?? Life Science Business Development Innovation

    If you missed our Webinar discussing solutions to unmet needs in GLP1 cardiometabolic clinical trials, please check out the recording.

    查看Clinical ink的公司主页,图片

    8,192 位关注者

    Did you miss our webinar??Register now to watch the recording!?Many thanks to the panel for this insightful conversation about solving unmet needs in?#GLP1?#cardiometabolic?#clinicaltrials. Moderator: Tom Dougherty, Data Science & AI Innovative Partnership Lead at Novo Nordisk, and Panelists:?Jonathan Goldman, MD MBA ATP, CEO of Clinical ink,? Kevin Dolgin, Co-Founder of Observia, Chris Bennani, Managing Director and Partner at Boston Consulting Group (BCG), Steve Polyak, Ph.D., Vice President, Engineering and Data at Clinical ink, and? David Anderson, Principal Scientist at Clinical ink Register here: https://lnkd.in/eRfdjcpH

    • 该图片无替代文字
  • 查看Clinical ink的公司主页,图片

    8,192 位关注者

    Did you miss our webinar??Register now to watch the recording!?Many thanks to the panel for this insightful conversation about solving unmet needs in?#GLP1?#cardiometabolic?#clinicaltrials. Moderator: Tom Dougherty, Data Science & AI Innovative Partnership Lead at Novo Nordisk, and Panelists:?Jonathan Goldman, MD MBA ATP, CEO of Clinical ink,? Kevin Dolgin, Co-Founder of Observia, Chris Bennani, Managing Director and Partner at Boston Consulting Group (BCG), Steve Polyak, Ph.D., Vice President, Engineering and Data at Clinical ink, and? David Anderson, Principal Scientist at Clinical ink Register here: https://lnkd.in/eRfdjcpH

    • 该图片无替代文字
  • Clinical ink转发了

    查看Connor M.的档案,图片

    Operating Partner at GI Partners

    Amazing work by Steve Polyak, Ph.D. and team at Clinical ink and their launch of their new GlucoseReady solution.

    查看Clinical ink的公司主页,图片

    8,192 位关注者

    Today we announce the launch of GlucoseReady?, an integrated GCP compliant digital platform designed for the new era of cardiometabolic clinical trials. The suite of tools including disease specific electronic clinical outcomes assessments (eCOA), behavioral assessment by the SPUR? tool, lifestyle standardization, blood (BGM) and continuous glucose monitoring (CGM), digital weight scale and actigraphy.?Unique endpoint features include ability of BGM and CGM to trigger hypoglycemia eCOA within the platform in line with the latest FDA guidance.?Unique compliance features include prediction, tracking and prevention of non-compliance and drop out at site and patient level. Partnerships with leading digital device developers further reinforce alignment with FDA expectation for regulatory compliance. ? Together, GlucoseReady? provides modules which used separately or together support multiple therapeutic areas including diabetes, chronic weight management and obesity and NASH/MASH, within a single GCP platform. It is specifically designed for user friendliness, patient and site support, as well as the requirements of an FDA inspection. https://lnkd.in/e2Df6A9p ? Learn more at our webinar on May 7: https://lnkd.in/eRfdjcpH ? ? #GlucoseReady #Innovation #ClinicalTrials #CardiometabolicDisease #DigitalHealth #Clinicalink

    • 该图片无替代文字
  • Clinical ink转发了

    查看Michael C. Olenick的档案,图片

    VP, Project Management at Clinical Ink

    I am proud to be a part of this incredible frontier in data collection. Register for the webinar to learn how Clinical Ink can enable your Cardiometabolic clinical trial.

    查看Clinical ink的公司主页,图片

    8,192 位关注者

    Today we announce the launch of GlucoseReady?, an integrated GCP compliant digital platform designed for the new era of cardiometabolic clinical trials. The suite of tools including disease specific electronic clinical outcomes assessments (eCOA), behavioral assessment by the SPUR? tool, lifestyle standardization, blood (BGM) and continuous glucose monitoring (CGM), digital weight scale and actigraphy.?Unique endpoint features include ability of BGM and CGM to trigger hypoglycemia eCOA within the platform in line with the latest FDA guidance.?Unique compliance features include prediction, tracking and prevention of non-compliance and drop out at site and patient level. Partnerships with leading digital device developers further reinforce alignment with FDA expectation for regulatory compliance. ? Together, GlucoseReady? provides modules which used separately or together support multiple therapeutic areas including diabetes, chronic weight management and obesity and NASH/MASH, within a single GCP platform. It is specifically designed for user friendliness, patient and site support, as well as the requirements of an FDA inspection. https://lnkd.in/e2Df6A9p ? Learn more at our webinar on May 7: https://lnkd.in/eRfdjcpH ? ? #GlucoseReady #Innovation #ClinicalTrials #CardiometabolicDisease #DigitalHealth #Clinicalink

    • 该图片无替代文字
  • Clinical ink转发了

    查看Stuart Roeves的档案,图片

    Vice President | Clinical Ink

    Introducing GlucoseReady?, a GCP compliant digital platform tailored for modern cardiometabolic clinical trials. Our suite includes disease-specific eCOA, SPUR? behavioral assessment, lifestyle standardization tools, BGM/CGM, digital weight scale, and actigraphy. Unique features allow BGM/CGM to trigger hypoglycemia eCOA, enhancing compliance with FDA guidelines. Predictive tracking prevents non-compliance and dropouts. Partnering with top digital developers ensures regulatory alignment. GlucoseReady? supports diabetes, weight management, obesity, NASH/MASH, with user-friendly design and FDA inspection readiness. #ClinicalTrials #DigitalHealth

    查看Clinical ink的公司主页,图片

    8,192 位关注者

    Today we announce the launch of GlucoseReady?, an integrated GCP compliant digital platform designed for the new era of cardiometabolic clinical trials. The suite of tools including disease specific electronic clinical outcomes assessments (eCOA), behavioral assessment by the SPUR? tool, lifestyle standardization, blood (BGM) and continuous glucose monitoring (CGM), digital weight scale and actigraphy.?Unique endpoint features include ability of BGM and CGM to trigger hypoglycemia eCOA within the platform in line with the latest FDA guidance.?Unique compliance features include prediction, tracking and prevention of non-compliance and drop out at site and patient level. Partnerships with leading digital device developers further reinforce alignment with FDA expectation for regulatory compliance. ? Together, GlucoseReady? provides modules which used separately or together support multiple therapeutic areas including diabetes, chronic weight management and obesity and NASH/MASH, within a single GCP platform. It is specifically designed for user friendliness, patient and site support, as well as the requirements of an FDA inspection. https://lnkd.in/e2Df6A9p ? Learn more at our webinar on May 7: https://lnkd.in/eRfdjcpH ? ? #GlucoseReady #Innovation #ClinicalTrials #CardiometabolicDisease #DigitalHealth #Clinicalink

    • 该图片无替代文字
  • Clinical ink转发了

    查看Ashley Kopp的档案,图片

    Business Development at Clinical ink

    Exciting news!! Today is the official launch of GlucoseReady?, an integrated suite of eClinical tools for cardiometabolic clinical trials! Learn more at our webinar on May 7: https://lnkd.in/eRfdjcpH

    查看Clinical ink的公司主页,图片

    8,192 位关注者

    Today we announce the launch of GlucoseReady?, an integrated GCP compliant digital platform designed for the new era of cardiometabolic clinical trials. The suite of tools including disease specific electronic clinical outcomes assessments (eCOA), behavioral assessment by the SPUR? tool, lifestyle standardization, blood (BGM) and continuous glucose monitoring (CGM), digital weight scale and actigraphy.?Unique endpoint features include ability of BGM and CGM to trigger hypoglycemia eCOA within the platform in line with the latest FDA guidance.?Unique compliance features include prediction, tracking and prevention of non-compliance and drop out at site and patient level. Partnerships with leading digital device developers further reinforce alignment with FDA expectation for regulatory compliance. ? Together, GlucoseReady? provides modules which used separately or together support multiple therapeutic areas including diabetes, chronic weight management and obesity and NASH/MASH, within a single GCP platform. It is specifically designed for user friendliness, patient and site support, as well as the requirements of an FDA inspection. https://lnkd.in/e2Df6A9p ? Learn more at our webinar on May 7: https://lnkd.in/eRfdjcpH ? ? #GlucoseReady #Innovation #ClinicalTrials #CardiometabolicDisease #DigitalHealth #Clinicalink

    • 该图片无替代文字

相似主页

查看职位

融资